Drug giant invests $300 million in 23andMe and the promise of genetics
The pharma company GlaxoSmithKline will team with 23andMe on developing new drugs, it said in a statement.
What: The $300 million investment in 23andMe shows how drug companies are betting on human genetics to decide what medicines to pursue. Hal Barron, Glaxo’s R&D boss, said the deal was part of an effort to speed up the drug search.
The database: It’s huge and getting bigger. 23andMe has DNA data on more than five million people, which it collected by selling them ancestry and health tests.
The business model: 23andMe has been looking to parlay its gene bank into drugs for a while now. It has other partners, like Pfizer, but this investment is the largest so far.
Richard Scheller, head of 23andMe’s drug team, described his company’s efforts as “nascent.” It does not yet have a drug in human testing, for example.
Treating brains: The companies said one of their first projects would be to develop a drug for Parkinson’s disease.
Deep Dive
Biotechnology and health
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
The quest to legitimize longevity medicine
Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.
There is a new most expensive drug in the world. Price tag: $4.25 million
But will the latest gene therapy suffer the curse of the costliest drug?
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.